Biotricity Appoints Casey Shattuck as New VP of Sales to Spearhead Bioflux Launch


Biotricity Inc. (BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced the company has appointed Mr. Casey Shattuck to serve as the Company’s Vice President of Sales. With extensive experience in building and leading sales divisions of cardiac and vascular “start-up” companies which have led to numerous successful acquisitions, Mr. Shattuck’s immediate priority will be to oversee the commercialization of Bioflux, a real-time, high-precision mobile cardiac telemetry solution for customers.

The appointment comes after the Company’s recent 510(k) clearance for its Bioflux device with the U.S. Food and Drug Administration (FDA) which occurred in December 2017. Bioflux’s advanced technology is designed to assist in the diagnosis of cardiac arrhythmias, enhance patient outcomes, and curb healthcare costs. The Company expects to have Bioflux in key sites in the U.S. by end of Q2 2018.

Mr. Shattuck brings vast industry expertise having helped establish Cardio Thoracic Systems as the dominant player in the southern US market, which the Company believes played a pivotal role in Guidant’s decision to acquire Cardio Thoracic Systems. At Foxhollow Technologies, Casey was responsible for 10 regional directors and 70 sales professionals with over $40 million in revenue.

“Management believes that commercialization is one of the most important milestones that a medical technology company can achieve,” said Waqaas Al-Siddiq, Founder and CEO of Biotricity. “We are thrilled to add Mr. Shattuck to our team and are confident in his ability to oversee our near-term growth catalysts. His expertise blends seamlessly with our world-class sales force, which comprises of highly driven and visionary team members from the medical and cardiac industries. We look forward to working with him as we aggressively target commercial launch during the second quarter of 2018.”

The Bioflux system is designed to be a complete solution for cardiac monitoring and diagnosis, consisting of the Bioflux device, proprietary software, and a 24/7 monitoring center that merges seamlessly with physicians’ existing platforms and workflows. Unlike traditional cardiac monitoring solutions, Bioflux extends the support a patient receives at a care facility into the patient’s home. The device monitors a patient’s ECG in near real-time, constantly analyzing and collecting data on the device and periodically uploading to the cloud via embedded cellular technology.

To learn more, visit www.biotricity.com.



March 26, 2018


Topic Area: Press Release


Recent Posts

Harris Health to Build New Freestanding Cancer Center

The center is planned to open in 2029, following the opening of the new O'Quinn Hospital along the North Loop at Lockwood.


Inland Empire Health Plan Opens Expanded San Bernardino Community Wellness Center

The new 33,000-square-foot center is nearly three times the size of the original location off Second Street.


Rethinking Parking Lot Design at Irvine Heritage Medical Plaza

A new solar installation shows how healthcare facilities can improve parking amenities while boosting energy savings


Repurposing Healthcare Spaces: 5 Critical Questions

Done well, converting existing spaces can trim upfront project costs by up to 40 percent, compared with ground-up construction


Disinfectant Contact Time: The Case for Biofilm Disruption

Contact time, while essential for compliance, does not reliably predict microbial reduction on actual healthcare surfaces.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.